A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) - Full Text View

Sponsor:	Human Genome Sciences
Collaborator:	GlaxoSmithKline
Information provided by:	Human Genome Sciences
ClinicalTrials.gov Identifier:	NCT00424476

Purpose

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active SLE disease.

Condition	Intervention	Phase
Systemic Lupus Erythematosus	Drug: belimumab Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)

Resource links provided by NLM:

MedlinePlus related topics: Lupus

Drug Information available for: Belimumab

U.S. FDA Resources

Further study details as provided by Human Genome Sciences:

Primary Outcome Measures:

At Wk52, the percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score and no worsening in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Percent of subjects with 4 points reduction from baseline in SELENA SLEDAI score at Wk 52. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
Mean change in PGA at Wk 24. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Mean change in SF-36 Health Survey physical component summary score (PCS) at Wk 24. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Percent of subjects whose average prednisone dose has been reduced by ≥ 25% from baseline to ≤ 7.5 mg/day during Weeks 40 through 52 [ Time Frame: Weeks 40 through 52 ] [ Designated as safety issue: No ]

Enrollment:	867
Study Start Date:	May 2007
Study Completion Date:	July 2009
Primary Completion Date:	July 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Belimumab 1mg/kg	Drug: belimumab 1mg/kg, IV (in the vein) on Days 0, 14, 28, and every 28 days through 48 weeks with a final evaluation at Week 52
2: Experimental Belimumab 10mg/kg	Drug: belimumab 10mg/kg, IV (in the vein) on Days 0, 14, 28 and every 28 days through 48 weeks with a final evaluation at Week 52
3: Placebo Comparator Placebo	Drug: Placebo IV (in the vein) on Days 0, 14, 28, and every 28 days through 52 weeks

Detailed Description:

The purpose of this SLE trial study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active Systemic Lupus Erythematosus (SLE) disease.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Key Inclusion Criteria:

Clinical diagnosis of SLE by ACR criteria.
Active SLE disease.
On stable SLE treatment regimen.

Key Exclusion Criteria:

Pregnant or nursing
Have received treatment with any B cell targeted therapy.
Have received treatment with a biological investigational agent in the past year.
Have received IV cyclophosphamide within 180 days of Day 0.
Have severe lupus kidney disease.
Have active central nervous system (CNS) lupus.
Have required management of acute or chronic infections within the past 60 days.
Have current drug or alcohol abuse or dependence.
Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00424476

Show 104 Study Locations

Sponsors and Collaborators

Human Genome Sciences

GlaxoSmithKline

Investigators

Study Director:

William Freimuth, MD, PhD

Human Genome Sciences, Inc.

More Information

Additional Information:

www.bliss-study.com This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Human Genome Sciences, Inc. ( William Freimuth, MD, PhD/Vice President of Clinical Research, Immunology, Rheumatology and Infectious Diseases )
Study ID Numbers:	HGS1006-C1057, BLISS-52
Study First Received:	January 17, 2007
Last Updated:	September 22, 2009
ClinicalTrials.gov Identifier:	NCT00424476 History of Changes
Health Authority:	United States: Food and Drug Administration; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Brazil: Ministry of Health; Chile: Instituto de Salud Publica de Chile; India: Ministry of Health; Romania: Ministry of Public Health; Korea: Food and Drug Administration; Taiwan: Department of Health; Philippines: Department of Health; Australia: National Health and Medical Research Council; Hong Kong: Department of Health; Russia: Ministry of Health and Social Development of the Russian Federation; Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos; Peru: General Directorate of Pharmaceuticals, Devices, and Drugs

Keywords provided by Human Genome Sciences:

SLE
Lupus
Systemic Lupus Erythematosus

Antibodies
Autoimmune Diseases
Belimumab

Additional relevant MeSH terms:

Autoimmune Diseases
Immune System Diseases
Lupus Erythematosus, Systemic
Connective Tissue Diseases

ClinicalTrials.gov processed this record on February 08, 2010